JP2002542182A - 粘膜上の可溶性ウイルス特異リガンドの半減期を増加させる方法 - Google Patents

粘膜上の可溶性ウイルス特異リガンドの半減期を増加させる方法

Info

Publication number
JP2002542182A
JP2002542182A JP2000611895A JP2000611895A JP2002542182A JP 2002542182 A JP2002542182 A JP 2002542182A JP 2000611895 A JP2000611895 A JP 2000611895A JP 2000611895 A JP2000611895 A JP 2000611895A JP 2002542182 A JP2002542182 A JP 2002542182A
Authority
JP
Japan
Prior art keywords
specific ligand
virus
bacterial
bacteria
chimeric molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000611895A
Other languages
English (en)
Japanese (ja)
Inventor
リー，ピーター・ピイ
Original Assignee
オセル・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オセル・インコーポレーテッド filed Critical オセル・インコーポレーテッド
Publication of JP2002542182A publication Critical patent/JP2002542182A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2000611895A 1999-04-16 2000-04-14 粘膜上の可溶性ウイルス特異リガンドの半減期を増加させる方法 Pending JP2002542182A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12972299P 1999-04-16 1999-04-16
US60/129,722 1999-04-16
PCT/US2000/010079 WO2000062758A1 (en) 1999-04-16 2000-04-14 A method for improving the half-life of soluble viral-specific ligands on mucosal membranes

Publications (1)

Publication Number Publication Date
JP2002542182A true JP2002542182A (ja) 2002-12-10

Family

ID=22441292

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000611895A Pending JP2002542182A (ja) 1999-04-16 2000-04-14 粘膜上の可溶性ウイルス特異リガンドの半減期を増加させる方法

Country Status (7)

Country Link
US (2) US6365156B1 (de)
EP (1) EP1171098A4 (de)
JP (1) JP2002542182A (de)
CN (1) CN1355690A (de)
AU (1) AU4350400A (de)
CA (1) CA2369762A1 (de)
WO (1) WO2000062758A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610293B1 (en) * 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
JP2006514636A (ja) * 2002-12-02 2006-05-11 バイオシネクサス インコーポレーテッド 抗ブドウ球菌療法およびワクチンの標的としての壁テイコイン酸
US20050244402A1 (en) * 2004-04-30 2005-11-03 Villanueva Julie M Absorption of pain-causing agents
WO2005116071A2 (en) * 2004-05-28 2005-12-08 University Of Massachusetts Snares for pathogenic or infectious agents and uses related thereto
EP1786445B1 (de) 2004-08-25 2011-06-08 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Lebendige mikrobielle mikrobizide
CN101437532B (zh) 2006-05-05 2013-08-21 冈戈根股份有限公司 噬菌体衍生的抗微生物活性剂
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
US8846053B2 (en) 2008-09-26 2014-09-30 Sdg, Inc. Orally bioavailable lipid-based constructs
US9145453B2 (en) * 2007-09-28 2015-09-29 Sdg, Inc. Orally bioavailable lipid-based constructs
US20100080773A1 (en) 2008-09-26 2010-04-01 Sdg, Inc. Orally Bioavailable Lipid-Based Constructs
JP2011501958A (ja) 2007-10-29 2011-01-20 バージニア テック インテレクチュアル プロパティーズ インコーポレーテッド ブタＤＣ−ＳＩＧＮ、ＩＣＡＭ−３およびＬＳＥＣｔｉｎならびにそれらの使用
US20110044968A1 (en) * 2008-03-10 2011-02-24 Pharmal N Corporation Compositions for treatment with metallopeptidases, methods of making and using the same
CN102617738B (zh) * 2011-01-26 2013-07-31 中国科学院武汉病毒研究所 重组融合蛋白cld的多肽、编码序列及制备方法和应用
US10233219B2 (en) 2013-04-12 2019-03-19 Tufts Medical Center Methods and systems for designing and/or characterizing soluble lipidated ligand agents
ES2805037T3 (es) 2016-01-22 2021-02-10 Tufts Medical Ct Inc Compuestos y métodos para tratar la inflamación
JP7071933B2 (ja) * 2016-02-25 2022-05-19 アプライド バイオロジカル ラボラトリーズ インコーポレイテッド 浮遊病原体および刺激物に対して防御するための組成物および方法
CN106282178B (zh) * 2016-09-05 2019-06-04 南京农业大学 重组嗜酸乳杆菌s层蛋白在大肠杆菌中的高效表达及其应用
US11077173B2 (en) 2017-03-13 2021-08-03 Sdg, Inc. Lipid-based nanoparticles and methods using same
CN110612114A (zh) 2017-03-13 2019-12-24 Sdg公司 具有增强的稳定性的基于脂质的纳米颗粒

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834589A (en) * 1990-12-14 1998-11-10 New York University Chimeric viral receptor polypeptides
CA2104958A1 (en) 1991-03-07 1992-09-08 Jean C. Nichols Use of cell surface receptor targeted molecules for the treatment of viral diseases
US5348867A (en) 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
HU220420B (hu) 1992-03-13 2002-01-28 The Rockefeller University Gram-pozitív baktériumok hibrid sejtfelszíni fehérjéje, eljárás és készlet fertőzés kimutatására
US5531988A (en) 1994-10-28 1996-07-02 Metagenics, Inc. Bacteria and immunoglobulin-containing composition for human gastrointestinal health
US5733540A (en) * 1995-03-08 1998-03-31 Lee; Peter Poon-Hang Protection from viral infection via colonization of mucosal membranes with genetically modified bacteria

Also Published As

Publication number Publication date
WO2000062758A1 (en) 2000-10-26
EP1171098A4 (de) 2003-04-02
CN1355690A (zh) 2002-06-26
EP1171098A1 (de) 2002-01-16
US20020086020A1 (en) 2002-07-04
AU4350400A (en) 2000-11-02
CA2369762A1 (en) 2000-10-26
US6365156B1 (en) 2002-04-02

Similar Documents

Publication Publication Date Title
JP6889199B2 (ja) ｐ９７のフラグメントおよびその使用
JP2002542182A (ja) 粘膜上の可溶性ウイルス特異リガンドの半減期を増加させる方法
JP4716350B2 (ja) 潜伏期膜タンパク質に対する抗体およびそれらの使用
CA2926698C (en) Chimeric antigen receptor t cell switches and uses thereof
JP4482054B2 (ja) 細胞内の物質移送のための抗体から誘導されたベクター
JP4741086B2 (ja) 新規のＦａｂフラグメントライブラリーおよびそれらの使用方法
JP4185151B2 (ja) ＨＩＶｇｐ１２０の加水分解を触媒する組成物および方法
EP2267032A2 (de) Verfahren zur Verabreichung therapeutischer Polypeptide und Polypeptide dafür
CN102307896A (zh) 基于ⅲ型纤连蛋白结构域的支架组合物、方法及用途
CN102596992A (zh) 基于ⅲ型纤连蛋白结构域的支架组合物、方法及用途
US20190022244A1 (en) Blood-brain barrier vector compounds and conjugates thereof
JP2002534121A (ja) 新規な複合体形成タンパク質
AU675449B2 (en) Reshaped monocolonal antibodies against an immunoglobulin isotype
US9493538B2 (en) Snares for pathogenic or infectious agents and uses related thereto
WO2018176732A1 (zh) 与cd56分子特异性结合的多肽及其应用
AU769259B2 (en) Polymeric immunoglobulin receptor (pIgR)-binding domains and methods of use therefor
JPH03103175A (ja) ハイブリッドモノクローナル抗体，抗体産生ポリドーマおよび抗体含有薬剤
CN112292393A (zh) 双功能血脑疗法
US20110212119A1 (en) Methods for making hiv vaccines and related compositions
US20220144906A1 (en) Bifunctional blood brain therapies for interleukin-1 related diseases
KR100504130B1 (ko) Ｉｃａｍ－１ 결합 단백질 및 이를 코딩하는폴리뉴클레오티드, 상기 폴리뉴클레오티드를 포함하는벡터 및 숙주세포, 상기 단백질을 포함하는 조성물
DE69636924T2 (de) Zusammensetzungen und methoden zur katalysierten hydrolyse von hiv gp120
Baker Brachmann et al. Overview: Fusion proteins: Fundamental and therapeutic applications
JPH0372873A (ja) ネコ×マウスヘテロハイブリドーマおよびネコ免疫グロブリンλ鎖の定常領域をコードする遺伝子断片
JPH10237099A (ja) 糖脂質糖鎖レプリカペプチド